A Participatory Approach to Support Glucose Tolerance Tracking in Real-Life of Patients Wi
Recent studies show that lifestyle interventions, such as exercise, healthy diet, and education, can help prevent type 2 diabetes in high-risk individuals, and even reverse the disease in its early stages. However, not many methods have been developed to use modern technology to help people manage their diabetes in a m
| Condition(s) | Type 2 Diabetes Mellitus, Non Insulin Dependent |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Recent studies show that lifestyle interventions, such as exercise, healthy diet, and education, can help prevent type 2 diabetes in high-risk individuals, and even reverse the disease in its early stages. However, not many methods have been developed to use modern technology to help people manage their diabetes in a more active way, in line with participatory medicine, where patients play a key role in their treatment. In this study, the investigators propose an e-health approach to automatically collect health data from patients, including information from continuous glucose monitor (CGM) and other health tracking devices, in real-life conditions. The investigators will also develop a simple and easy-to-understand tool to track patient's metabolic status and will analyze how it relates t |
| Who can participate | Inclusion Criteria: * Non-insulin treated T2D diagnosis (not treated at all or only with metformin); * Physically inactive (less than 150 minutes/week of moderate physical activity); * Age between 40 and 70; * HbA1c below 8.5%. Exclusion Criteria: * Diabetes diagnosis less than 3 years before the study initiation; * Pregnancy; * Symptomatic heart disease, e.g. history of myocardial infarction, coronary bypass, stenting procedure, angina, or any ischemic cerebrovascular event; * Use of a medication that significantly impacts glucose metabolism (oral steroids); * Use of a medication that significantly lowers heart rate (beta blockers, reserpine, guanethidine, methyldopa, clonidine, cimetidine, digitalis, calcium channel blockers, amiodarone, antiarrhythmic drugs, or lithium); * Atrial fibril |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Lead sponsor | Enea Parimbelli |
| Locations | Pavia, Pavia, Italy |
| Start date | 2025-05 |
| NCT ID | NCT06864546 |
| Official listing | https://clinicaltrials.gov/study/NCT06864546 |